top of page

Clinical remission data for Stelara in Crohn’s disease presented at DDW

New Phase III data shows that a significantly greater proportion of adult patients with moderate to severe Crohn’s disease receiving Janssen’sStelara (ustekinumab) subcutaneous (SC) maintenance therapy were in clinical remission at one year.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page